89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated CirrhosisGlobeNewsWire • Wednesday
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with FibrosisGlobeNewsWire • 03/12/24
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to TradeZacks Investment Research • 03/05/24
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease TreatmentInvestors Business Daily • 03/04/24
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 02/29/24
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/06/24
Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect?Zacks Investment Research • 01/10/24
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 12/12/23
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 12/07/23
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 12/06/23
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024GlobeNewsWire • 12/04/23
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)GlobeNewsWire • 11/27/23
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023GlobeNewsWire • 11/12/23
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/08/23
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor ConferenceGlobeNewsWire • 10/17/23